Pharmaceuticals

Intravenous Immunoglobulin Market Performance Outlook 2026–2030: Revenue to Hit $23.44 Billion at 8.6% CAGR

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the intravenous immunoglobulin market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Intravenous Immunoglobulin Market in 2026, and what figure is it projected to hit by 2030?

The intravenous immunoglobulin market size has shown substantial growth in recent years. It is anticipated to increase from $15.57 billion in 2025 to $16.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. This historical expansion can be linked to the rising prevalence of primary immunodeficiency diseases, advancements in immunoglobulin purification techniques, an increase in hospital-based IVIG administration, growing awareness about autoimmune disorders, and the expansion of IVIG production facilities.

The intravenous immunoglobulin market size is projected to experience robust expansion in the coming years, set to reach $23.44 billion by 2030, driven by a compound annual growth rate (CAGR) of 8.6%. This anticipated growth is influenced by a rising demand for home-based IVIG therapy, the emergence of biosimilar IVIG products, the adoption of automated infusion technologies, broader applications in neurological conditions, and the expansion of immunoglobulin therapies into emerging markets. Key trends shaping the forecast period encompass personalized immunoglobulin therapy, the implementation of home-based IVIG administration, the advancement and acceptance of biosimilars, improved purification and safety measures, and the utilization of automated infusion systems.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Which Drivers Are Affecting Market Participation In The Intravenous Immunoglobulin Market?

The expanding geriatric population is projected to propel the intravenous immunoglobulin market. This demographic comprises individuals over 65 years of age. As people age, their immune systems often falter, leading to an inadequacy of antibodies. Thus, they require immunoglobulins to acquire these vital antibodies. This consequently boosts the demand for intravenous immunoglobulins and fosters the advancement of the intravenous immunoglobulin market. As an illustration, in January 2024, the Population Reference Bureau, a Kenya-based Nonprofit organization, reported that the number of Americans aged 65 and older is anticipated to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. Concurrently, this age group’s percentage of the total population is also expected to climb from 17% to 23% within the same period. Consequently, the expanding geriatric population will be a key factor driving the growth of the intravenous immunoglobulin market.

What Segment Categories Are Covered In The Intravenous Immunoglobulin Market?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

What Trends Are Projected To Support The Growth Of The Intravenous Immunoglobulin Market?

Companies prominent within the intravenous immunoglobin market are concentrating on launching novel products, like plasma-derived medications, and securing approval from governmental bodies, such as the US FDA, to enhance their market competitiveness. The launch of an innovative IVIG solution endorsed by the FDA indicates the U.S. Food and Drug Administration’s endorsement of a new intravenous immunoglobulin (IVIG) treatment for particular health issues. For example, during June 2024, Biotest AG, a German firm specializing in plasma proteins and products, declared its initial U.S. Food and Drug Administration (FDA) approval for Yimmugo, intended for managing primary immunodeficiencies. Yimmugo, an intravenous immunoglobulin, comprises aggregated human plasma-derived immunoglobulin G (IgG), vital for bolstering the immune system in individuals with PIDs. This approval occurs amidst rising demand for therapies derived from plasma, underscoring the necessity for efficacious treatments for those with weakened immune systems. Yimmugo expands Grifols’ current portfolio of intravenous and subcutaneous immunoglobulins, offering additional choices for patients who depend on these crucial medications.

Which Key Market Players Are Investing In Expansion And Innovation Within The Intravenous Immunoglobulin Market?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Regions Are Poised For Strategic Growth In The Intravenous Immunoglobulin Market?

North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Intravenous Immunoglobulin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

Browse Through More Reports Similar to the Global Intravenous Immunoglobulin Market 2026, By The Business Research Company

Intravenous Immunoglobulin Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Immunoglobulins Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report

Subcutaneous Immunoglobulin Scig Market Report 2026

https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795